Related references
Note: Only part of the references are listed.Circulating angiogenic factors are related to the severity of gestational hypertension and preeclampsia, and their adverse outcomes
Alfredo Leanos-Miranda et al.
MEDICINE (2017)
Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia
Harald Zeisler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Soluble Endoglin, Transforming Growth Factor-Beta 1 and Soluble Tumor Necrosis Factor Alpha Receptors in Different Clinical Manifestations of Preeclampsia
Luiza O. Perucci et al.
PLOS ONE (2014)
Circulating Angiogenic Factors and Urinary Prolactin as Predictors of Adverse Outcomes in Women With Preeclampsia
Alfredo Leanos-Miranda et al.
HYPERTENSION (2013)
Hypertension in Pregnancy Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy
James M. Roberts et al.
OBSTETRICS AND GYNECOLOGY (2013)
Angiogenic Factors and the Risk of Adverse Outcomes in Women With Suspected Preeclampsia
Sarosh Rana et al.
CIRCULATION (2012)
Changes in circulating concentrations of soluble fms-like tyrosine kinase-1 and placental growth factor measured by automated electrochemiluminescence immunoassays methods are predictors of preeclampsia
Alfredo Leanos-Miranda et al.
JOURNAL OF HYPERTENSION (2012)
Plasma Concentrations of Soluble Endoglin versus Standard Evaluation in Patients with Suspected Preeclampsia
Sarosh Rana et al.
PLOS ONE (2012)
An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia
Stefan Verlohren et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2010)
A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate
Roberto Romero et al.
JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE (2008)
Protein:: Creatinine ratio in random urine samples is a reliable marker of increased 24-hour protein excretion in hospitalized women with hypertensive disorders of pregnancy
Alfredo Leanos-Miranda et al.
CLINICAL CHEMISTRY (2007)
Current CHS and NHBPEP criteria for severe preeclampsia do not uniformly predict adverse maternal or perinatal outcomes
J. Menzies et al.
HYPERTENSION IN PREGNANCY (2007)
Soluble endoglin (sEng) joins the soluble fms-like tyrosine kinase (sFlt) receptor as a pre-eclampsia molecule
Friedrich C. Luft
NEPHROLOGY DIALYSIS TRANSPLANTATION (2006)
Soluble endoglin and other circulating antiangiogenic factors in preeclampsia
Richard J. Levine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Prediction of maternal complications and adverse infant outcome at admission for temporizing management of early-onset severe hypertensive disorders of pregnancy
Wessel Ganzevoort et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2006)
Soluble endoglin contributes to the pathogenesis of preeclampsia
Shivalingappa Venkatesha et al.
NATURE MEDICINE (2006)
Circulating angiogenic factors and the risk of preeclampsia
RJ Levine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy
RW Gifford et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2000)
Share Paper
